Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post‐transplant Recurrence: Final Results of the ALLY‐1 Study: 2016 ACG Presidential Poster Award: 774. (October 2016)